Latest Insurance News

Opyl Limited’s AI platform TrialKey has partnered with UK insurer Innovatrix to launch a pioneering parametric insurance product that protects biotech firms from the financial risks of clinical trial failures.

Emyria has landed a multi-year funding deal with Medibank to support its Empax PTSD program at Perth Clinic, marking a first for private insurer-backed psychotherapy in Australia. The company also announces a $4 million capital raise to fuel national expansion.

Dubber Corporation has initiated court proceedings against its former auditors following a $26.6 million misappropriation uncovered in FY24, aiming to restore financial stability by year-end.

Control Bionics is on track for its strongest financial year yet, driven by robust US and Australian sales and promising global trials of its NeuroStrip® device.

Challenger Limited has welcomed APRA’s consultation on new capital settings for annuity products, highlighting the potential for regulatory reforms to boost innovation and growth in Australia’s retirement income sector.

Mesoblast reports positive FDA progress on accelerated approval for Revascor in ischemic heart failure and plans a pivotal trial to extend Ryoncil’s label to adults with graft versus host disease, while its US commercial launch outpaces expectations.

Tower Limited has confirmed Paul Johnston as its permanent CEO after a successful interim period, while initiating a search for a new CFO to sustain its financial leadership.

Johns Lyng Group has received a conditional, non-binding acquisition proposal from Pacific Equity Partners, sparking a potential shift in ownership with key management poised to retain stakes. The company has granted exclusivity for due diligence, setting the stage for a possible binding offer.

Helia Group announces the departure of CEO Pauline Blight-Johnston after five years, appointing CFO Michael Cant as interim CEO amid evolving market conditions. The leadership change signals a strategic pivot for the lender mortgage insurer.

Kore Potash has signed non-binding term sheets with OWI-RAMS for a $2.2 billion funding package to develop its flagship Kola Potash Project in the Republic of Congo, combining senior secured finance and royalty-based funding under Shariah principles.

Monash IVF has disclosed a significant embryo transfer error at its Clayton laboratory, prompting an internal investigation and expanded independent review. The company is implementing new safeguards while maintaining its profit outlook.

Tyro Payments has announced the resignation of CEO Jon Davey, who will remain for up to six months to ensure a smooth leadership transition. Davey’s tenure saw significant transformation and strategic groundwork for future expansion.